Anti-angiogenic Drug Aggravates the Degree of Anti-resorptive Drug-based Medication-related Osteonecrosis of the Jaw by Impairing the Proliferation and Migration Function of Gingival Fibroblasts

Overview

Journal BMC Oral Health

Publisher Biomed Central

Specialty Dentistry

Date 2023 May 27

PMID 37245004

Authors

Ning Zhao

Qing-Xiang Li

Yi-Fei Wang

Qiao Qiao

Hong-Yuan Huang

Chuan-Bin Guo

Yu-Xing Guo

Affiliations

Soon will be listed here.

Abstract

Background: Long-term use of anti-resorptive or anti-angiogenic drugs in cancer patients with odontogenic infections may lead to medication-related osteonecrosis of the jaw (MRONJ). This study investigated whether anti-angiogenic agents aggravate MRONJ occurrence in anti-resorptive-treated patients.

Methods: The clinical stage and jawbone exposure of MRONJ patients caused by different drug regimens were analyzed to ascertain the aggravation effect of anti-angiogenic drugs on anti-resorptive drug-based MRONJ. Next, a periodontitis mice model was established, and tooth extraction was performed after administering anti-resorptive and/or anti-angiogenic drugs; the imaging and histological change of the extraction socket were observed. Moreover, the cell function of gingival fibroblasts was analyzed after the treatment with anti-resorptive and/or anti-angiogenic drugs in order to evaluate their effect on the gingival tissue healing of the extraction socket.

Results: Patients treated with anti-angiogenic and anti-resorptive drugs had an advanced clinical stage and a bigger proportion of necrotic jawbone exposure compared to patients treated with anti-resorptive drugs alone. In vivo study further indicated a greater loss of mucosa tissue coverage above the tooth extraction in mice treated with sunitinib (Suti) + zoledronate (Zole) group (7/10) vs. Zole group (3/10) and Suti group (1/10). Micro-computed tomography (CT) and histological data showed that the new bone formation in the extraction socket was lower in Suti + Zole and Zole groups vs. Suti and control groups. In vitro data showed that the anti-angiogenic drugs had a stronger inhibitory ability on the proliferation and migration function of gingival fibroblasts than anti-resorptive drugs, and the inhibitory effect was obviously enhanced after combining zoledronate and sunitinib.

Conclusion: Our findings provided support for a synergistic contribution of anti-angiogenic drugs to anti-resorptive drugs-based MRONJ. Importantly, the present study revealed that anti-angiogenic drugs alone do not induce severe MRONJ but aggravate the degree of MRONJ via the enhanced inhibitory function of gingival fibroblasts based on anti-resorptive drugs.

Citing Articles

Knowledge and attitudes of undergraduate dental students at the University of Barcelona regarding antiresorptive and antiangiogenic medications: A cross-sectional study.

Fuentes-Cazar K, Toledano-Serrabona J, Alves F, Sanchez-Torres A, Figueiredo R, Gay-Escoda C J Clin Exp Dent. 2024; 16(10):e1217-e1223.

PMID: 39544216 PMC: 11559107. DOI: 10.4317/jced.62092.

Inflammation Can Be a High-Risk Factor for Mucosal Nonunion of MRONJ by Regulating SIRT1 Signaling When Treated with an Oncologic Dose of Zoledronate.

Zhu S, Cui Y, Zhang W, Ji Y, Li L, Luo S Drug Des Devel Ther. 2024; 18:2793-2812.

PMID: 38979400 PMC: 11229984. DOI: 10.2147/DDDT.S456811.

Clinical Performance of Implant-Supported Prostheses in the Rehabilitation of Patients Previously Treated for Medication-Related Osteonecrosis of the Jaws (MRONJ): A Systematic Review.

Anitua E, Alkhraisat M, Eguia A Cureus. 2024; 16(6):e61658.

PMID: 38966469 PMC: 11223626. DOI: 10.7759/cureus.61658.

Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.

Bassan Marinho Maciel G, Maciel R, Linhares Ferrazzo K, Cademartori Danesi C J Mol Med (Berl). 2024; 102(3):353-364.

PMID: 38302741 DOI: 10.1007/s00109-024-02425-9.

Rodents as an animal model for studying tooth extraction-related medication-related osteonecrosis of the jaw: assessment of outcomes.

Hadad H, Matheus H, Pai S, Souza F, Guastaldi F Arch Oral Biol. 2023; 159():105875.

PMID: 38160519 PMC: 11729500. DOI: 10.1016/j.archoralbio.2023.105875.

References

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

Sacco R, Woolley J, Patel G, Calasans-Maia M, Yates J . Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?. Br J Oral Maxillofac Surg. 2022; 60(2):e216-e230. DOI: 10.1016/j.bjoms.2021.03.006. View

Yuan A, Munz A, Reinert S, Hoefert S . Gingival fibroblasts and medication-related osteonecrosis of the jaw: Results by real-time and wound healing in vitro assays. J Craniomaxillofac Surg. 2019; 47(9):1464-1474. DOI: 10.1016/j.jcms.2019.06.004. View

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

Chang Y, Li J, Mirhaidari G, Zbinden J, Barker J, Blum K . Zoledronate alters natural progression of tissue-engineered vascular grafts. FASEB J. 2021; 35(10):e21849. PMC: 8647171. DOI: 10.1096/fj.202001606RR. View

Bi Y, Gao Y, Ehirchiou D, Cao C, Kikuiri T, Le A . Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010; 177(1):280-90. PMC: 2893671. DOI: 10.2353/ajpath.2010.090592. View

Li C, Lu W, Seneviratne C, Leung W, Zwahlen R, Zheng L . Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats. Clin Oral Implants Res. 2014; 27(1):1-6. DOI: 10.1111/clr.12502. View

Barnsley J, Buckland G, Chan P, Ong A, Ramos A, Baxter M . Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res. 2021; 33(4):759-773. PMC: 8084810. DOI: 10.1007/s40520-021-01817-y. View

Toljanic J, Bedard J, Larson R, Fox J . A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer. 1999; 85(8):1843-8. View

10.

Ito S, Kasahara N, Kitamura K, Matsunaga S, Mizoguchi T, Htun M . Pathological differences in the bone healing processes between tooth extraction socket and femoral fracture. Bone Rep. 2022; 16:101522. PMC: 8965168. DOI: 10.1016/j.bonr.2022.101522. View

11.

Smith P, Martinez C, Martinez J, McCulloch C . Role of Fibroblast Populations in Periodontal Wound Healing and Tissue Remodeling. Front Physiol. 2019; 10:270. PMC: 6491628. DOI: 10.3389/fphys.2019.00270. View

12.

Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I . Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010; 122(1):181-8. DOI: 10.1007/s10549-010-0866-3. View

13.

Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas M, Tsakalos G . Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009; 76(3):209-11. DOI: 10.1159/000201931. View

14.

Sivolella S, Lumachi F, Stellini E, Favero L . Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res. 2013; 33(5):1793-7. View

15.

Zirlik K, Duyster J . Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat. 2018; 41(4):166-171. DOI: 10.1159/000488087. View

16.

Barker T . The role of ECM proteins and protein fragments in guiding cell behavior in regenerative medicine. Biomaterials. 2011; 32(18):4211-4. DOI: 10.1016/j.biomaterials.2011.02.027. View

17.

Gill S, Parks W . Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol. 2007; 40(6-7):1334-47. PMC: 2746915. DOI: 10.1016/j.biocel.2007.10.024. View

18.

Leite de Marcelos P, Perez D, Soares D, de Araujo S, Evencio L, Pontual M . The effects of zoledronic acid on the progression of experimental periodontitis in rats: histological and microtomographic analyses. J Periodontal Implant Sci. 2021; 51(4):264-275. PMC: 8367644. DOI: 10.5051/jpis.2001100055. View

19.

Tamari T, Elimelech R, Cohen G, Cohen T, Doppelt O, Eskander-Hashoul L . Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. Sci Rep. 2019; 9(1):18896. PMC: 6906486. DOI: 10.1038/s41598-019-55383-5. View

20.

Sabrkhany S, Griffioen A, Pineda S, Sanders L, Mattheij N, van Geffen J . Sunitinib uptake inhibits platelet function in cancer patients. Eur J Cancer. 2016; 66:47-54. DOI: 10.1016/j.ejca.2016.07.016. View